Search

Your search keyword '"Steg, Ph. Gabriel"' showing total 902 results
Start Over Author "Steg, Ph. Gabriel"
902 results on '"Steg, Ph. Gabriel"'

53. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

Author

Roe, Matthew T., Li, Qian H., Bhatt, Deepak L., Bittner, Vera A., Diaz, Rafael, Goodman, Shaun G., Harrington, Robert A., Jukema, J. Wouter, Lopez-Jaramillo, Patricio, Lopes, Renato D., Louie, Michael J., Moriarty, Patrick M., Szarek, Michael, Vogel, Robert, White, Harvey D., Zeiher, Andreas M., Baccara-Dinet, Marie T., Steg, Ph. Gabriel, and Schwartz, Gregory G.

Published
2019
Full Text
View/download PDF

55. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease

Author

Hageman, Steven H. J., McKay, Ailsa J., Ueda, Peter, Gunn, Laura H., Jernberg, Tomas, Hagström, Emil, Bhatt, Deepak L., Steg, Ph. Gabriel, Läll, Kristi, Mägi, Reedik, Gynnild, Mari Nordbø, Ellekjær, Hanne, Saltvedt, Ingvild, Tuñón, José, Mahíllo, Ignacio, Aceña, Álvaro, Kaminski, Karol, Chlabicz, Malgorzata, Sawicka, Emilia, Tillman, Taavi, McEvoy, John W., di Angelantonio, Emanuele, Graham, Ian, de Bacquer, Dirk, Ray, Kausik K., Dorresteijn, Jannick A. N., Visseren, Frank L. J., Asselbergs, F. W., Nathoe, H. M., de Borst, G. J., Bots, M. L., Geerlings, M. I., Emmelot, M. H., de Jong, P. A., Leiner, T., Lely, A. T., van der Kaaij, N. P., Kappelle, L. J., Ruigrok, Y. M., Verhaar, M. C., Visseren, F. L. J., Westerink, J., Halle, Martin, Timmis, Adam D., Lettino, Maddalena, Vardas, Panos E., McEvoy, John William, Graham, Ian M., and Academic Medical Center

Subjects
Cardiac & Cardiovascular Systems, PREDICTION, Myocardial Infarction, Residual risk, Risk Assessment, ARTERIAL-DISEASE, Recurrent risk, Risk Factors, Medicine and Health Sciences, Humans, Cardiac and Cardiovascular Systems, 1102 Cardiorespiratory Medicine and Haematology, METAANALYSIS, Science & Technology, Kardiologi, Secondary prevention, 1103 Clinical Sciences, ASSOCIATION, Atherosclerosis, Established ASCVD, COMPETING RISKS, PREVENTION, Risk prediction, Stroke, ASPIRIN, Cardiovascular System & Hematology, Cardiovascular Diseases, CLINICAL-PRACTICE, Personalized treatment, Cardiovascular System & Cardiology, Cardiology and Cardiovascular Medicine, OUTPATIENTS, Life Sciences & Biomedicine, Algorithms, Biomarkers, TASK-FORCE
Abstract

Aims The 10-year risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events in patients with established ASCVD can be estimated with the Secondary Manifestations of ARTerial disease (SMART) risk score, and may help refine clinical management. To broaden generalizability across regions, we updated the existing tool (SMART2 risk score) and recalibrated it with regional incidence rates and assessed its performance in external populations. Methods and results Individuals with coronary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysms were included from the Utrecht Cardiovascular Cohort-SMART cohort [n = 8355; 1706 ASCVD events during a median follow-up of 8.2 years (interquartile range 4.2-12.5)] to derive a 10-year risk prediction model for recurrent ASCVD events (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular mortality) using a Fine and Gray competing risk-adjusted model. The model was recalibrated to four regions across Europe, and to Asia (excluding Japan), Japan, Australia, North America, and Latin America using contemporary cohort data from each target region. External validation used data from seven cohorts [Clinical Practice Research Datalink, SWEDEHEART, the international REduction of Atherothrombosis for Continued Health (REACH) Registry, Estonian Biobank, Spanish Biomarkers in Acute Coronary Syndrome and Biomarkers in Acute Myocardial Infarction (BACS/BAMI), the Norwegian COgnitive Impairment After STroke, and Bialystok PLUS/Polaspire] and included 369 044 individuals with established ASCVD of whom 62 807 experienced an ASCVD event. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] in BACS/BAMI to 0.772 (95% CI 0.659-0.886) in REACH Europe high-risk region. The clinical utility of the model was demonstrated across a range of clinically relevant treatment thresholds for intensified treatment options. Conclusion The SMART2 risk score provides an updated, validated tool for the prediction of recurrent ASCVD events in patients with established ASCVD across European and non-European populations. The use of this tool could allow for a more personalized approach to secondary prevention based upon quantitative rather than qualitative estimates of residual risk. Key objective To improve upon prediction of 10-year residual atherosclerotic cardiovascular disease (ASCVD) event risk in individuals with established ASCVD, by taking into account competing risks and geographical differences in ASCVD incidence. Key findings Derivation in 8355 individuals with established ASCVD from the Utrecht Cardiovascular Cohort-Secondary Manifestations of ARTerial disease (SMART) cohort. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] to 0.772 (95% CI 0.659-0.886). Clinical utility was demonstrated across a range of treatment thresholds relevant to therapy intensification. Take-home messages The SMART2 risk score can be used to estimate 10-year residual risk of fatal and non-fatal ASCVD in individuals with established ASCVD. Adapted to the CVD incidence in several global regions. Facilitates shared decision-making on Step 2 prevention goals as recommended by the 2021 ESC Guidelines on cardiovascular prevention.

Published
2022

58. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial.

Author

Aggarwal, Rahul, Bhatt, Deepak L., Szarek, Michael, Leiter, Lawrence A., Cannon, Christopher P., Lopes, Renato D., Davies, Michael J, Banks, Phillip, Pitt, Bertram, and Steg, Ph. Gabriel

Subjects
TYPE 2 diabetes, CHRONIC kidney failure, MEDICAL research, WOMEN'S hospitals
Abstract

A post hoc analysis of the SCORED randomized trial examined the time to clinical benefit with sotagliflozin, a medication used to treat type 2 diabetes and chronic kidney disease. The study found that sotagliflozin reduced the risk of heart failure outcomes in patients with these conditions. The analysis showed that the benefits of sotagliflozin were observed as early as 95 days after randomization and were sustained throughout the study period. The findings suggest that initiating therapy with sotagliflozin quickly may lead to meaningful improvements in heart failure outcomes. [Extracted from the article]

Published
2024
Full Text
View/download PDF

60. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX

Author

Olivier, Christoph B., Bhatt, Deepak L., Leonardi, Sergio, Stone, Gregg W., Gibson, C. Michael, Steg, Ph. Gabriel, Hamm, Christian W., Wilson, Matthew D., Mangum, Stacey, Price, Matthew J., Prats, Jayne, White, Harvey D., Lopes, Renato D., Harrington, Robert A., and Mahaffey, Kenneth W.

Published
2019
Full Text
View/download PDF

62. Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up

Author

Alnasser, Sami M.A., Huang, Wei, Gore, Joel M., Steg, Ph. Gabriel, Eagle, Kim A., Anderson, Frederick A., Jr., Fox, Keith A.A., Gurfinkel, Enrique, Brieger, David, Klein, Werner, van de Werf, Frans, Avezum, Álvaro, Montalescot, Gilles, Gulba, Dietrich C., Budaj, Andrzej, Lopez-Sendon, Jose, Granger, Christopher B., Kennelly, Brian M., Goldberg, Robert J., Fleming, Emily, and Goodman, Shaun G.

Published
2015
Full Text
View/download PDF

63. Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin: Insights From the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI])

Author

White, Harvey D., Bhatt, Deepak L., Gibson, C. Michael, Hamm, Christian W., Mahaffey, Kenneth W., Price, Matthew J., Steg, Ph. Gabriel, Stone, Gregg W., Cortese, Bernardo, Wilensky, Michael, Deliargyris, Efthymios N., Liu, Tiepu, Prats, Jayne, and Harrington, Robert A.

Published
2015
Full Text
View/download PDF

64. Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

Author

Schwartz, Gregory G., primary, Szarek, Michael, additional, Zeiher, Andreas, additional, White, Harvey D., additional, Jukema, J. Wouter, additional, Harrington, Robert A., additional, Goodman, Shaun G., additional, Diaz, Rafael, additional, Bittner, Vera, additional, Bhatt, Deepak L., additional, and Steg, Ph. Gabriel, additional

Published
2022
Full Text
View/download PDF

69. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

Author

Ridker, Paul M, primary, Rifai, Nader, additional, MacFadyen, Jean, additional, Glynn, Robert J., additional, Jiao, Lixia, additional, Steg, Ph. Gabriel, additional, Miller, Michael, additional, Brinton, Eliot A., additional, Jacobson, Terry A., additional, Tardif, Jean-Claude, additional, Ballantyne, Christie M., additional, Mason, R. Preston, additional, and Bhatt, Deepak L., additional

Published
2022
Full Text
View/download PDF

76. Reduction in Revascularization With Icosapent Ethyl

Author

Peterson, Benjamin E., Bhatt, Deepak L., Steg, Ph. Gabriel, Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Ketchum, Steven B., Juliano, Rebecca A., Jiao, Lixia, Doyle, Ralph T., Granowitz, Craig, Gibson, C. Michael, Pinto, Duane, Giugliano, Robert P., Budoff, Matthew J., Tardif, Jean-Claude, Verma, Subodh, and Ballantyne, Christie M.

Subjects
Male, eicosapentaenoic acid, prevention & control, Middle Aged, icosapent ethyl, Double-Blind Method, myocardial revascularization, Cardiovascular Diseases, Original Research Articles, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, Diabetes Mellitus, Humans, Female, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Platelet Aggregation Inhibitors, Aged, Follow-Up Studies
Abstract

Supplemental Digital Content is available in the text., Background: Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. Methods: REDUCE-IT (The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial), a multicenter, double-blind, placebo-controlled trial, randomly assigned statin-treated patients with elevated triglycerides (135–499 mg/dL), controlled low-density lipoprotein (41–100 mg/dL), and either established cardiovascular disease or diabetes plus other risk factors to receive icosapent ethyl 4 g/d or placebo. The primary and key secondary composite end points were significantly reduced. Prespecified analyses examined all coronary revascularizations, recurrent revascularizations, and revascularization subtypes. Results: A total of 8179 randomly assigned patients were followed for 4.9 years (median). First revascularizations were reduced to 9.2% (22.5/1000 patient-years) with icosapent ethyl versus 13.3% (33.7/1000 patient-years) with placebo (hazard ratio, 0.66 [95% CI, 0.58–0.76]; P

Published
2020

77. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease : the updated SMART2 algorithm

Author

Hageman, Steven H. J., McKay, Ailsa J., Ueda, Peter, Gunn, Laura H., Jernberg, Tomas, Hagström, Emil, Bhatt, Deepak L., Steg, Ph Gabriel, Lall, Kristi, Magi, Reedik, Gynnild, Mari Nordbo, Ellekjaer, Hanne, Saltvedt, Ingvild, Tunon, Jose, Mahillo, Ignacio, Acena, Alvaro, Kaminski, Karol, Chlabicz, Malgorzata, Sawicka, Emilia, Tillman, Taavi, McEvoy, John W., Di Angelantonio, Emanuele, Graham, Ian, De Bacquer, Dirk, Ray, Kausik K., Dorresteijn, Jannick A. N., Visseren, Frank L. J., Hageman, Steven H. J., McKay, Ailsa J., Ueda, Peter, Gunn, Laura H., Jernberg, Tomas, Hagström, Emil, Bhatt, Deepak L., Steg, Ph Gabriel, Lall, Kristi, Magi, Reedik, Gynnild, Mari Nordbo, Ellekjaer, Hanne, Saltvedt, Ingvild, Tunon, Jose, Mahillo, Ignacio, Acena, Alvaro, Kaminski, Karol, Chlabicz, Malgorzata, Sawicka, Emilia, Tillman, Taavi, McEvoy, John W., Di Angelantonio, Emanuele, Graham, Ian, De Bacquer, Dirk, Ray, Kausik K., Dorresteijn, Jannick A. N., and Visseren, Frank L. J.

Abstract

Aims The 10-year risk of recurrent atherosclerotic cardiovascular disease (ASCVD) events in patients with established ASCVD can be estimated with the Secondary Manifestations of ARTerial disease (SMART) risk score, and may help refine clinical management. To broaden generalizability across regions, we updated the existing tool (SMART2 risk score) and recalibrated it with regional incidence rates and assessed its performance in external populations. Methods and results Individuals with coronary artery disease, cerebrovascular disease, peripheral artery disease, or abdominal aortic aneurysms were included from the Utrecht Cardiovascular Cohort-SMART cohort [n = 8355; 1706 ASCVD events during a median follow-up of 8.2 years (interquartile range 4.2-12.5)] to derive a 10-year risk prediction model for recurrent ASCVD events (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular mortality) using a Fine and Gray competing risk-adjusted model. The model was recalibrated to four regions across Europe, and to Asia (excluding Japan), Japan, Australia, North America, and Latin America using contemporary cohort data from each target region. External validation used data from seven cohorts [Clinical Practice Research Datalink, SWEDEHEART, the international REduction of Atherothrombosis for Continued Health (REACH) Registry, Estonian Biobank, Spanish Biomarkers in Acute Coronary Syndrome and Biomarkers in Acute Myocardial Infarction (BACS/BAMI), the Norwegian COgnitive Impairment After STroke, and Bialystok PLUS/Polaspire] and included 369 044 individuals with established ASCVD of whom 62 807 experienced an ASCVD event. C-statistics ranged from 0.605 [95% confidence interval (CI) 0.547-0.664] in BACS/BAMI to 0.772 (95% CI 0.659-0.886) in REACH Europe high-risk region. The clinical utility of the model was demonstrated across a range of clinically relevant treatment thresholds for intensified treatment options. Conclusion The SMART2 risk score provides an updated, v

Published
2022
Full Text
View/download PDF

79. Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial.

Author

Schwartz, Gregory G, Szarek, Michael, Bhatt, Deepak L, Bittner, Vera A, Bujas-Bobanovic, Maja, Diaz, Rafael, Fazio, Sergio, Fras, Zlatko, Goodman, Shaun G, Harrington, Robert A, Jukema, J Wouter, Manvelian, Garen, Pordy, Robert, Ray, Kausik K, Scemama, Michel, White, Harvey D, Steg, Ph Gabriel, and Investigators, for the ODYSSEY OUTCOMES

Subjects
LDL cholesterol, ACUTE coronary syndrome, MAJOR adverse cardiovascular events, CARDIOVASCULAR diseases risk factors, PATIENT compliance
Abstract

Aims Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after trial end). It is unknown whether legacy effects follow a short period of very low low-density lipoprotein cholesterol (LDL-C) levels achieved with statin plus proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. Methods and results In 18 924 patients with recent acute coronary syndrome, the ODYSSEY OUTCOMES trial compared the PCSK9 inhibitor alirocumab with placebo, each added to high-intensity or maximum-tolerated statin therapy. Patients with two consecutive LDL-C levels <0.39 mmol/L (15 mg/dL) on alirocumab had blinded placebo substitution for the remainder of the trial with continued statin treatment. In post hoc analyses, major adverse cardiovascular events (MACE) in these patients were compared to MACE in propensity score–matched patients from the placebo group with similar baseline characteristics and study medication adherence. In the alirocumab group, 730 patients had blinded placebo substitution at a median of 8.3 months from randomization, after a median of 6.0 months with LDL-C <0.39 mmol/L. They were matched to 1460 placebo patients. Both groups had lower baseline LDL-C and lipoprotein(a) and better study medication adherence than those of the overall cohort. Over a median follow-up of 2.8 years, MACE occurred in 47 (6.4%) alirocumab patients with limited-duration, very low achieved LDL-C vs. 122 (8.4%) matched placebo patients (treatment hazard ratio 0.72; 95% confidence interval 0.51, 0.997; P = 0.047). Conclusion A short period of LDL-C levels <0.39 mmol/L achieved with statin and alirocumab, followed by statin monotherapy, was associated with a lower risk of MACE than statin monotherapy throughout the observation period. Clinical benefit persisted for several years. Trial registration ClinicalTrials.gov NCT01663402 [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

83. An International Model to Predict Recurrent Cardiovascular Disease

Author

Wilson, Peter W.F., D'Agostino, Ralph, Sr, Bhatt, Deepak L., Eagle, Kim, Pencina, Michael J., Smith, Sidney C., Alberts, Mark J., Dallongeville, Jean, Goto, Shinya, Hirsch, Alan T., Liau, Chiau-Suong, Ohman, E. Magnus, Röther, Joachim, Reid, Christopher, Mas, Jean-Louis, and Steg, Ph. Gabriel

Published
2012
Full Text
View/download PDF

84. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION

Author

Peterson, Benjamin E., primary, Harrington, Robert A., additional, Stone, Gregg W., additional, Steg, Ph. Gabriel, additional, Gibson, C. Michael, additional, Hamm, Christian W., additional, Price, Matthew J., additional, Lopes, Renato D., additional, Leonardi, Sergio, additional, Prats, Jayne, additional, Deliargyris, Efthymios N., additional, Mahaffey, Kenneth W., additional, White, Harvey D., additional, and Bhatt, Deepak L., additional

Published
2022
Full Text
View/download PDF

85. Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery

Author

Bhatt, Deepak L., primary, Pollack, Charles V., additional, Mazer, C. David, additional, Angiolillo, Dominick J., additional, Steg, Ph. Gabriel, additional, James, Stefan K., additional, Weitz, Jeffrey I., additional, Ramnath, Rohit, additional, Arnold, Susan E., additional, Mays, Michael C., additional, Umstead, Bret R., additional, White, Barbara, additional, Hickey, Lisa L., additional, Jennings, Lisa K., additional, Curry, Benjamin J., additional, Lee, John S., additional, and Verma, Subodh, additional

Published
2022
Full Text
View/download PDF

88. REDUCE-IT USA

Author

Bhatt, Deepak L., Miller, Michael, Brinton, Eliot A., Jacobson, Terry A., Steg, Ph. Gabriel, Ketchum, Steven B., Doyle, Ralph T., Juliano, Rebecca A., Jiao, Lixia, Granowitz, Craig, Tardif, Jean-Claude, Olshansky, Brian, Chung, Mina K., Gibson, C. Michael, Giugliano, Robert P., Budoff, Matthew J., and Ballantyne, Christie M.

Subjects
lipids, fatty acids, omega-3, Original Research Articles, eicosapentaenoic acid ethyl ester, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, prevention and control, triglycerides, United States
Abstract

Supplemental Digital Content is available in the text., Background: Some trials have found that patients from the United States derive less benefit than patients enrolled outside the United States. This prespecified REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl - Intervention Trial) subgroup analysis was conducted to determine the degree of benefit of icosapent ethyl in the United States. Methods: REDUCE-IT randomized 8179 statin-treated patients with qualifying triglycerides ≥135 and 40 and ≤100 mg/dL and a history of atherosclerosis or diabetes mellitus to icosapent ethyl 4 g/d or placebo. The primary composite end point was cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. The key secondary composite end point was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. A hierarchy was prespecified for examination of individual and composite end points. Results: A total of 3146 US patients (38.5% of the trial) were randomized and followed for a median of 4.9 years; 32.3% were women and 9.7% were Hispanic. The primary composite end point occurred in 24.7% of placebo-treated patients versus 18.2% of icosapent ethyl-treated patients (hazard ratio [HR], 0.69 [95% CI, 0.59–0.80]; P=0.000001); the key secondary composite end point occurred in 16.6% versus 12.1% (HR, 0.69 [95% CI, 0.57–0.83]; P=0.00008). All prespecified hierarchical end points were meaningfully and significantly reduced, including cardiovascular death (6.7% to 4.7%; HR, 0.66 [95% CI, 0.49–0.90]; P=0.007), myocardial infarction (8.8% to 6.7%; HR, 0.72 [95% CI, 0.56–0.93]; P=0.01), stroke (4.1% to 2.6%; HR, 0.63 [95% CI, 0.43–0.93]; P=0.02), and all-cause mortality (9.8% to 7.2%; HR, 0.70 [95% CI, 0.55–0.90]; P=0.004); for all-cause mortality in the US versus non-US patients, Pinteraction=0.02. Safety and tolerability findings were consistent with the full study cohort. Conclusions: Whereas the non-US subgroup showed significant reductions in the primary and key secondary end points, the US subgroup demonstrated particularly robust risk reductions across a variety of individual and composite end points, including all-cause mortality. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01492361.

Published
2019

89. The Incidence of Bradyarrhythmias and Clinical Bradyarrhythmic Events in Patients With Acute Coronary Syndromes Treated With Ticagrelor or Clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) Trial: Results of the Continuous Electrocardiographic Assessment Substudy

Author

Scirica, Benjamin M., Cannon, Christopher P., Emanuelsson, Håkan, Michelson, Eric L., Harrington, Robert A., Husted, Steen, James, Stefan, Katus, Hugo, Pais, Prem, Raev, Dimitar, Spinar, Jindrich, Steg, Ph. Gabriel, Storey, Robert F., and Wallentin, Lars

Published
2011
Full Text
View/download PDF

93. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

Author

Cavender, Matthew A., primary, Harrington, Robert A., additional, Stone, Gregg W., additional, Steg, Ph. Gabriel, additional, Gibson, C. Michael, additional, Hamm, Christian W., additional, Price, Matthew J., additional, Lopes, Renato D., additional, Leonardi, Sergio, additional, Deliargyris, Efthymios N., additional, Prats, Jayne, additional, Mahaffey, Kenneth W., additional, White, Harvey D., additional, Bhatt, Deepak L., additional, Huber, Kurt, additional, Lima, Valter C., additional, Jorgova-Makedonska, Julia B., additional, Widimský, Petr, additional, Kobulia, Bondo, additional, Radke, Peter W., additional, Bramucci, Ezio, additional, Witkowski, Adam, additional, Shlyakhto, Evgeny, additional, Van de Werf, Frans, additional, Faxon, David P., additional, Ohman, E. Magnus, additional, Verheugt, Freek W.A., additional, Weaver, W. Douglas, additional, Tijssen, Jan G.P., additional, Wilson, Matthew, additional, Mangum, Stacey, additional, Melloni, Chiara, additional, Brennan, Matthew J., additional, Tricoci, Pierluigi, additional, Harrison, Robert, additional, Barros, Pedro, additional, Armaganijan, Luciana, additional, Anderson, Monique, additional, Bagai, Akshay, additional, Généreux, Philippe, additional, Brener, Sorin J., additional, LaSalle, Laura, additional, Benzer, Werner, additional, Delle-Karth, Georg, additional, Leisch, Franz, additional, Abdalla Saad, Jamil, additional, Abizaid, Alexandre, additional, Augusto Formiga Areas, Carlos, additional, Ribeiro, Expedito E., additional, Rossi Dos Santos, Fabio, additional, Tadeu Tumelero, Rogerio, additional, Vieira Botelho, Roberto, additional, Atzev, Borislav, additional, Boichev, Boicho, additional, Grigorov, Georgi, additional, Penkov, Nikolay, additional, Petrov, Ivo, additional, Zehirov, Boris, additional, Cervinka, Pavel, additional, Coufal, Zdenek, additional, Hajek, Petr, additional, Horak, David, additional, Kala, Petr, additional, Kmonicek, Petr, additional, Kocka, Viktor, additional, Mrozek, Jan, additional, Simek, Stanislav, additional, Sitar, Jan, additional, Stasek, Josef, additional, Tousek, Frantisek, additional, Chapidze, Gulnara, additional, Emukhvari, Nodar, additional, Khabeishvili, George, additional, Mamatsashvili, Merab, additional, Shaburishvili, Tamaz, additional, Behrens, Steffen, additional, Darius, Harald, additional, Dissmann, Martin, additional, Fichtlscherer, Stephan, additional, Franz, Wolfgang, additional, Geisler, Tobias, additional, Genth-Zotz, Sabine, additional, Goldmann, Britta, additional, Heuer, Hubertus, additional, Hoffmann, Stefan, additional, Mugge, Andreas, additional, Poerner, Tudor, additional, Radke, Peter, additional, Richardt, Gert, additional, Stellbrink, Christoph, additional, Werner, Nikos, additional, De Servi, Stefano, additional, Galasso, Gennaro, additional, Menozzi, Alberto, additional, Musumeci, Giuseppe, additional, Picchi, Andrea, additional, Presbitero, Patrizia, additional, Devlin, Gerard, additional, Sasse, Alexander, additional, Scott, Douglas, additional, Stewart, Ralph, additional, Andrzej, Szyszka, additional, Dubaniewicz, Witold, additional, Gasior, Zbigniew, additional, Kasprzak, Jaroslaw, additional, Kleinrok, Andrzej, additional, Kornacewicz-Jach, Zdzislawa, additional, Rynkiewicz, Andrzej, additional, Sosnowski, Cezary, additional, Targonski, Radoslaw, additional, Trebacz, Jaroslaw, additional, Zinka, Elzbieta, additional, Barbarash, Olga, additional, Dovgalevsky, Yakov, additional, Gordeev, Ivan, additional, Kalinina, Svetlana, additional, Kosmachova, Elena, additional, Markov, Valentin, additional, Pavlov, Prokhor, additional, Shalaev, Sergey, additional, Shogenov, Zaur, additional, Sukmanova, Irina, additional, Vasilieva, Elena, additional, Yakovlev, Alexey, additional, Boonbaichaiyapruck, Sarana, additional, Chamnarnphol, Noppadol, additional, Kaewsuwanna, Pinij, additional, Kuanprasert, Srun, additional, Piyayotai, Dilok, additional, Amine, Maged, additional, Angiolillo, Dominick, additional, Arif, Imran, additional, Blankenship, James, additional, Brilakis, Emmanouil, additional, Chan, Michael, additional, Cinderella, Joseph, additional, Davis, Brent, additional, Devireddy, Chandanreddy, additional, Dorogy, Mark, additional, Douglas, John, additional, Ferrier, Norman, additional, Fisher, Daniel, additional, Foster, Robert, additional, French, William, additional, Galla, John, additional, Gimple, Lawrence, additional, Gogia, Harinder, additional, Gogo, Prospero, additional, Gollapudi, Raghava, additional, Gruberg, Luis, additional, Hermiller, James, additional, Heuser, Richard, additional, Iwaoka, Robert, additional, Jafar, Zubair, additional, Kimmelstiel, Carey, additional, Kinlay, Scott, additional, Leggett, James, additional, Leimgruber, Pierre, additional, Letts, Dustin, additional, Lipsitt, Michael, additional, Low, Reginald, additional, Martinez-Arraras, Joaquin, additional, Mayhew, Marc, additional, McLaurin, Brent, additional, McWhirter, Paul, additional, Mirza, Ayoub, additional, Negus, Brian, additional, Nygaard, Thomas, additional, O’Riordan, William, additional, Paulus, Richard, additional, Petersen, John, additional, Picon, Hector, additional, Picone, Mark, additional, Rivera, Ernesto, additional, Rizik, David, additional, Rodriguez, Arsenio, additional, Saucedo, Jorge, additional, Scott, J. Christopher, additional, Sethi, Virender, additional, Shroff, Adhir, additional, Siegel, Craig, additional, Spriggs, Douglas, additional, Steinberg, Daniel, additional, Stillabower, Michael, additional, Stuckey, Thomas, additional, Suarez, Jose, additional, Tauth, Jeffrey, additional, Temizer, Dogan, additional, Vidovich, Mladen, additional, Voeltz, Michele, additional, Waltman, Jonathan, additional, and Wilensky, Michael, additional

Published
2021
Full Text
View/download PDF

95. The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

Author

Gutierrez, J. Antonio, Harrington, Robert A., Blankenship, James C., Stone, Gregg W., Steg, Ph. Gabriel, Gibson, C. Michael, Hamm, Christian W., Price, Matthew J., Généreux, Philippe, Prats, Jayne, Deliargyris, Efthymios N., Mahaffey, Kenneth W., White, Harvey D., Bhatt, Deepak L., Bhatt, DL, Stone, GW, Mahaffey, KW, Gibson, CM, Steg, PG, Hamm, CW, Price, MJ, Leonardi, S, Gallup, D, Bramucci, E, Radke, PW, Widimsky, P, Tousek, F, Tauth, J, Spriggs, D, McLaurin, BT, Angiolillo, DJ, Genereux, P, Liu, T, Prats, J, Todd, M, Skerjanec, S, White, HD, and Harrington, RA

Published
2016
Full Text
View/download PDF

96. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

Author

Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J., Borger, Michael A., Brotons, Carlos, Chew, Derek P., Gencer, Baris, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F., Windecker, Stephan, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thomas, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick-Smith, David, Huber, Kurt, Iliodromitis, Efstathios, James, Stefan, Lewis, Basil S., Lip, Gregory Y. H., Piepoli, Massimo F., Richter, Dimitrios, Rosemann, Thomas, Sechtem, Udo, Steg, Ph. Gabriel, Vrints, Christian, and Luis Zamorano, Jose

Published
2016
Full Text
View/download PDF

100. Enoxaparin Versus Unfractionated Heparin in Elective Percutaneous Coronary Intervention: 1-Year Results From the STEEPLE (SafeTy and Efficacy of Enoxaparin in Percutaneous coronary intervention patients, an internationaL randomized Evaluation) Trial

Author

Montalescot, Gilles, Gallo, Richard, White, Harvey D., Cohen, Marc, Steg, Ph. Gabriel, Aylward, Philip E.G., Bode, Christoph, Chiariello, Massimo, King, Spencer B., III, Harrington, Robert A., Desmet, Walter J., Macaya, Carlos, and Steinhubl, Steven R.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results